|
1）Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502
|
|
|
|
2）Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010; 56: 977-86
|
|
|
|
|
3）Miida T, Nishimura K, Okamura T, et al. A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: Comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis. 2012; 225: 208-15
|
|
|
|
|
|
4）Ai M, Tanaka A, Tomie N, et al. Triglyceride rich lipoprotein cholesterol exceeds low density lipoprotein cholesterol in patients with hypertriglyceridemia. Horm Metab Res. 2001; 33: 612-7
|
|
|
|
|
|
5）日本動脈硬化学会，編．動脈硬化性疾患予防ガイドライン2012
|
|
|
|
|
|
6）van Deventer HE, Miller WG, Myers GL, et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem. 2011; 57: 490-501
|
|
|
|
|
|
7）Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical Utility of different lipid measured for prediction of coronary heart disease in men and women. JAMA. 2007; 298: 776-85
|
|
|
|
|
|
8）Rifai N, Joubran R, Yu H, et al. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem. 1999; 45: 1967-73
|
|
|
|
|
|
9）Ridker PM, Danielson E, Fonseca FAH, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-207
|
|
|
|
|
|
10）Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999; 100: 230-35
|
|
|
|
|
|
11）Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-9
|
|
|
|
|
|
12）Elliott P, Chambers JC, Zhang W,et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009; 302: 37-48
|
|
|
|
|
|
13）Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009; 302: 49-57
|
|
|
|
|
|
14）Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23: 85-9
|
|
|
|
|
|
15）Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361: 226-8
|
|
|
|
|
|
16）Ai M, Otokozawa S, Asztalos BF, et al. Adiponectin: An independent risk factor for coronary heart disease in men in the Framingham Offspring Study. Atherosclerosis. 2011; 217: 543-8
|
|
|
|
|
|
17）von Eynatten M, Humpert PM, Bluemm A, et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis. 2008; 199; 123-8
|
|
|
|
|
|
18）Van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. Arch Neurol. 2012; 69: 594-600
|
|
|
|
|